Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
On August 22, 2025, Inspira Technologies announced the approval of a U.S. patent for its ART500 core technology, which is designed for low flow rates extracorporeal oxygenation. This patent is a significant milestone for the company, as it aims to penetrate a $20 billion market for advanced respiratory support. The ART500 system targets patients needing respiratory support but not requiring traditional high-flow ECMO systems, thus expanding Inspira’s market reach. This patent strengthens the company’s intellectual property portfolio and reinforces its leadership in advanced extracorporeal life support, providing a competitive edge and potential long-term value for shareholders.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Its products include the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., as well as the next-generation INSPIRA ART500 system. The company is also developing HYLA, a proprietary blood sensor platform for continuous, non-invasive monitoring. Inspira Technologies is positioned as a key player in the life-support and MedTech industry, focusing on strategic growth and potential partnerships.
Average Trading Volume: 1,063,075
Technical Sentiment Signal: Buy
Current Market Cap: $31.51M
For an in-depth examination of IINN stock, go to TipRanks’ Overview page.